Inhibitor Therapeutics (INTI) EBITDA (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly EBITDA came in at -$695632.0 in Q1 2026, down 3.13% YoY from -$718073.1 in Q1 2025, and up 47.1% on a QoQ basis from -$1.3 million in Q4 2025.
Inhibitor Therapeutics (INTI) EBITDA (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 15 years of EBITDA data on file, last reported at -$695632.0 in Q1 2026.
- Quarterly EBITDA fell 3.13% year-over-year to -$695632.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.4 million (up 3.08% YoY) and the FY2025 annual result came in at -$3.4 million, up 6.31% from the prior year.
- EBITDA improved to -$695632.0 in Q1 2026, from -$1.3 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$69987.0 in Q3 2022 to a low of -$1.5 million in Q4 2024.
- A 5-year average of -$696623.5 and a median of -$695773.0 in 2025 frame the typical range for EBITDA.
- The widest YoY moves for EBITDA: up 44.26% in 2022, down 1373.05% in 2022.
- Tracing INTI's EBITDA over 5 years: stood at -$423635.0 in 2022, then plunged by 200.56% to -$1.3 million in 2023, then slipped by 16.57% to -$1.5 million in 2024, then gained by 11.4% to -$1.3 million in 2025, then jumped by 47.1% to -$695632.0 in 2026.
- The last three EBITDA figures came in at -$695632.0 (Q1 2026), -$1.3 million (Q4 2025), and -$741215.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | -618,597.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -695,632.00 |
| Dec 31, 2025 | -1.32 Mn |
| Sep 30, 2025 | -741,215.00 |
| Jun 30, 2025 | -695,773.00 |
| Mar 31, 2025 | -674,551.00 |
| Dec 31, 2024 | -1.48 Mn |
| Sep 30, 2024 | -813,196.00 |
| Jun 30, 2024 | -585,147.00 |
| Mar 31, 2024 | -774,817.00 |
| Dec 31, 2023 | -1.27 Mn |
| Sep 30, 2023 | -759,528.00 |
| Jun 30, 2023 | -742,461.00 |
| Mar 31, 2023 | -629,724.00 |
| Dec 31, 2022 | -423,635.00 |
| Sep 30, 2022 | -69,987.00 |
| Jun 30, 2022 | -70,804.00 |
| Mar 31, 2022 | -93,500.00 |
| Dec 31, 2021 | -28,759.00 |
| Sep 30, 2021 | -66,248.00 |
| Jun 30, 2021 | -62,635.00 |